cbdMD Q2 Revenue Rises 19% to $5.64M Despite EPS Miss
cbdMD reported Q2 revenue of $5.64 million, beating estimates by $0.35 million and delivering 19% year-over-year and 12% sequential growth driven by core operations and its Bluebird Botanicals acquisition. However, EPS of -$0.08 missed the -$0.05 estimate, while a 0.044 debt-to-equity ratio and 2.82 current ratio highlight solid financial stability.
1. Q2 Revenue Performance
cbdMD recorded Q2 revenue of $5.64 million, surpassing the $5.29 million consensus by $0.35 million. This represents a 19% year-over-year increase and a 12% sequential rise driven by growth in its core product lines.
2. Earnings and Profitability
The company reported earnings per share of -$0.08, missing the -$0.05 estimate and reflecting continued unprofitability. This translated to a negative earnings yield of -103.8% and a trailing P/E ratio of -0.01.
3. Strategic Acquisition Impact
The recent acquisition of Bluebird Botanicals contributed to top-line growth and expanded cbdMD’s product portfolio in the cannabinoid market. Management highlighted integration efforts aimed at driving cross-brand synergies and cost efficiencies.
4. Financial Position
cbdMD maintains a low debt-to-equity ratio of 0.044 and a strong current ratio of 2.82, indicating healthy liquidity coverage for short-term obligations. Its price-to-sales ratio stands at 0.0015 and enterprise value-to-operating cash flow ratio at 1.45, underscoring attractive valuation metrics.